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OBJECTIVES: To determine the 12-month treatment retention
rates with risperidone long-acting injection (RLAI) treatment
in patients with schizophrenia enrolled in the electronic-
Schizophrenia Treatment Adherence Registry (e-STAR).
METHODS: E-STAR is a secure, web-based, international, long-
term observational study of patients with schizophrenia. Patients
were enrolled in the study when RLAI treatment was initiated.
Data are collected both retrospectively (1 year) and prospectively
(2 years). In this analysis, using the pooled data from Belgium,
Czech Republic, The Netherlands, Slovakia, Spain, and Sweden,
time on treatment was analyzed using Kaplan-Meier analysis and
proportional hazards regression. RESULTS: Total of 1847
patients from six European countries who completed 12-month
follow-up were included in this analysis. The majority of patients
were male (62.9%), with a mean age of 38.8  11.9 years old
and a mean time since diagnosis of 11.9  10.7 years. The most
common reasons for initiating RLAI were compliance (33.6%)
and insufﬁcient response to previous treatment (29.7%). At
12-months, 89.6% (95% conﬁdence internal: 88.2%–90.9%) of
patients were still being remained on RLAI. Proportional hazards
regression revealed that patients previously treated with oral
atypicals (p < 0.01) were less likely to discontinue whereas
patients previously treated with mood stabilizers (p < 0.05) or
were on polypharmacy of antipsychotics were more like to dis-
continue treatment. There were modest differences in treatment
retention among the six countries. CONCLUSION: In this
pooled interim analysis, nearly 90% of patients from 6 European
countries were still remained on RLAI treatment after 12
months. Further evaluation of treatment retention is ongoing as
patient accrual in e-STAR continues.
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OBJECTIVES: To examine whether the incidence of suicidal
ideation, violent behaviour, and deliberate self-harm changes in
patients with schizophrenia after 12-months of treatment with
Risperidone long-acting injection (RLAI) who are enrolled in
the electronic-Schizophrenia Treatment Adherence Registry
(e-STAR) in Czech Republic and Slovakia. METHODS: E-STAR,
a secure web-based, international, observational study of
patients with schizophrenia who have been initiated with RLAI.
Data are collected both retrospectively (1 year) and prospectively
(2 years). In this analysis data from Czech Republic and Slovakia
were pooled. RESULTS: To date a combined total of 1068
patients have been enrolled into e-STAR in Czech Republic and
Slovakia; 280 patients have been followed for at least 12-months
(156 Czech Republic, 124 Slovakia). Of the 280 patients, the
majority were male (57.9%) with a diagnosis of schizophrenia or
schizoaffective disorder (85.7%, 14.3% respectively) with a
mean age of 37  12.1 years and a mean time since diagnosis of
9.2  9 years. Compared to baseline, signiﬁcant decreases were
seen in the occurrence of suicidal ideation (18% to 1.1%,
p < 0.001), violent behaviour (15.5% to 0.4%, p = 0.001), and
self injury (8.6% to 0.4%, p < 0.001). Individual country results
were consistent with the pooled results. CONCLUSION:
Patients treated with RLAI for at least 12 months experienced
signiﬁcant decreases in the incidence of suicidal ideation, violent
behaviour, and self injury. Follow-up is ongoing until 24 months.
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OBJECTIVES: To assess the outcomes in patients initiated
on risperidone long-acting injection (RLAI) enrolled in the
electronic-Schizophrenia Treatment Adherence Registry (e-
STAR) and were followed for 12-months in the Czech Republic
and Slovakia. METHODS: E-STAR is a secure web-based, inter-
national, observational study of patients with schizophrenia who
have been initiated with RLAI. Data are collected both retrospec-
tively (1 year) and prospectively (2 years) including hospitali-
sations and reasons for treatment initiation; patients are
prospectively evaluated every 3 months using the Clinical Global
Impression Severity Scale (CGI-S) and Global Assessment of
Functioning Scale (GAF). RESULTS: To date a combined total of
1068 patients have been enrolled into e-STAR in the Czech
Republic and Slovakia; 280 patients have been followed for at
least 12-months (156 Czech Republic, 124 Slovakia). Of the 280
patients, the majority were male (57.9%) with a diagnosis of
schizophrenia or schizoaffective disorder (85.7%, 14.3% respec-
tively) with a mean age of 37  12.1 years and a mean time since
diagnosis of 9.2  9 years. At 12-months, 96.4% of patients
remained on RLAI treatment. 85.4% of patients were initiated
on 25 mg of RLAI at baseline and at 12-months 54.6% were still
on 25 mg. Compared to the 12-month retrospective period, sig-
niﬁcant decreases were seen in the 12-month prospective period
in the proportion of patients hospitalized (50% vs. 17.5%,
respectively; p < 0.001), the mean number of hospitalizations per
patient (0.65 vs. 0.23, p < 0.001), and the mean number of days
in hospital (29.6 vs. 7.7, p < 0.001). Signiﬁcant improvements
from baseline to 12 months were seen in both the average CGI-S
score (4.56 to 3.03, p < 0.001) and GAF score (48.7 to 71.3,
p < 0.001). CONCLUSION: Signiﬁcant improvement in disease
severity and functioning and decrease in use of hospital services
in patients with schizophrenia treated with RLAI were observed
in this 12-month interim analysis. Follow-up is ongoing until 24
months.
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